Exogenous regucalcin suppresses the growth of human liver cancer HepG2 cells in vitro

  • Authors:
    • Masayoshi Yamaguchi
    • Tomiyasu Murata
  • View Affiliations

  • Published online on: April 5, 2018     https://doi.org/10.3892/or.2018.6357
  • Pages: 2924-2930
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Regucalcin, which its gene is localized on the X chromosome, plays a pivotal role as a suppressor protein in signal transduction in various types of cells and tissues. Regucalcin gene expression has been demonstrated to be suppressed in various tumor tissues of animal and human subjects, suggesting a potential role of regucalcin in carcinogenesis. Regucalcin, which is produced from the tissues including liver, is found to be present in the serum of human subjects and animals. This study was undertaken to determine the effects of exogenous regucalcin on the proliferation in cloned human hepatoma HepG2 cells in vitro. Proliferation of HepG2 cells was suppressed after culture with addition of regucalcin (0.01 – 10 nM) into culture medium. Exogenous regucalcin did not reveal apoptotic cell death in HepG2 cells in vitro. Suppressive effects of regucalcin on cell proliferation were not enhanced in the presence of various signaling inhibitors including tumor necrosis factor-α (TNF-α), Bay K 8644, PD98059, staurosporine, worthomannin, 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) or gemcitabine, which were found to suppress the proliferation. In addition, exogenous regucalcin suppressed the formation of colonies of cultured hepatoma cells in vitro. These findings demonstrated that exogenous regucalcin exhibits a suppressive effect on the growth of human hepatoma HepG2 cells, proposing a strategy with the gene therapy for cancer treatment.
View Figures
View References

Related Articles

Journal Cover

June-2018
Volume 39 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yamaguchi M and Murata T: Exogenous regucalcin suppresses the growth of human liver cancer HepG2 cells in vitro. Oncol Rep 39: 2924-2930, 2018.
APA
Yamaguchi, M., & Murata, T. (2018). Exogenous regucalcin suppresses the growth of human liver cancer HepG2 cells in vitro. Oncology Reports, 39, 2924-2930. https://doi.org/10.3892/or.2018.6357
MLA
Yamaguchi, M., Murata, T."Exogenous regucalcin suppresses the growth of human liver cancer HepG2 cells in vitro". Oncology Reports 39.6 (2018): 2924-2930.
Chicago
Yamaguchi, M., Murata, T."Exogenous regucalcin suppresses the growth of human liver cancer HepG2 cells in vitro". Oncology Reports 39, no. 6 (2018): 2924-2930. https://doi.org/10.3892/or.2018.6357